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 Localized delivery of nucleic acids to target sites (e.g., diseased tissue) is 
critical for safe and effi cacious gene therapy. An ultrasound-based technique 
termed acoustic droplet vaporization (ADV) has been used to spatiotem-
porally control the release of therapeutic small molecules and proteins 
contained within sonosensitive emulsions. Here, ADV is used to control 
the release of lipoplex—containing plasmid DNA encoding an enhanced 
green fl uorescent protein reporter—from a sonosensitive emulsion. Focused 
ultrasound (3.5 MHz, mechanical index (MI) ≥ 1.5) generates robust release 
of fl uorescein (i.e., surrogate payload) and lipoplex from the emulsion. In situ 
release of the lipoplex from the emulsion using ADV (MI = 1.5, 30 cycles) 
yields a 55% release effi ciency, resulting in 43% transfection effi ciency and 
95% viability with C3H/10T1/2 cells. Without exposure to ultrasound, the 
release and transfection effi ciencies are 5% and 7%, respectively, with 99% 
viability. Lipoplex released by ADV retains its bioactivity while the ADV pro-
cess does not yield any measureable sonoporative enhancement of transfec-
tion. Co-encapsulation of Ficoll PM 400 within the lipoplex-loaded emulsion, 
and its subsequent release using ADV, yield higher transfection effi ciency 
than the lipoplex alone. The results demonstrate that ADV can have utility in 
the spatiotemporal control of gene delivery. 
 1.  Introduction 
 Gene therapy could greatly impact the 
treatment of many intractable and refrac-
tory diseases, both acquired and genetic. 
However, despite numerous clinical trials, 
no gene therapy products have yet been 
approved in the United States by the 
Food and Drug Administration (FDA). [ 1 ] 
One challenge in the clinical translation 
of gene therapy is the development of 
delivery vehicles for genes that are both 
safe and effective. The broad biodistribu-
tion of both viral and non-viral vectors 
can generate systemic side effects and 
elicit immunogenic responses. There-
fore, restricting the spatial localization of 
vectors to target sites (e.g., cells, tissues, 
organs) is critical for therapeutic effi cacy, 
while also minimizing transgene expres-
sion in non-target sites. At-site adminis-
tration of vectors—either vascularly (e.g., 
intrarterial) or avascularly (e.g., intratu-
moral)—can achieve tight spatial localiza-
tion, but this method is highly impractical 
for diffuse or inaccessible diseases. [ 2,3 ] 
 Both viral and non-viral vectors have been dosed systemically 
in clinical trials, with the latter vector accounting for ≈30% of 
trials. [ 4 ] Despite lower gene transfer effi ciencies, non-viral vec-
tors have been pursued due to their lower immunogenicity, 
ability to deliver large genetic payloads, ease of synthesis, and 
cost-effectiveness. Transport of naked DNA across the cell 
membrane is extremely limited so complexation with a chem-
ical vector is typically necessary. In the presented studies, non-
viral DNA is complexed with cationic lipids to form lipoplexes 
that bind electrostatically to the cell membrane, are uptaken 
by endocytosis, and eventually are released from the endo-
some such that DNA is transported to the nucleus. [ 5–7 ] When 
dosed intravenously, lipoplexes can display compromised 
stability, resulting from protein binding and degradation by 
nucleases; accumulation in the lung; and rapid clearance by 
the mononuclear phagocyte system. [ 8,9 ] Chemical modifi cation 
(e.g., pegylation, mannosylation) of lipoplexes can improve 
their pharmacokinetics, but spatial targeting remains a chal-
lenge. [ 10,11 ] These limitations can ultimately impact the effi cacy 
of non-viral gene delivery, localized uptake, and expression of 
the transgene. 
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 Ultrasound, which is used clinically for both diagnosis and 
treatment, has been investigated as one technique for improving 
targeted non-viral gene delivery. Ultrasound can be applied non-
invasively with spatiotemporal control and focused with sub-
millimeter precision to deeply located sites within the body. 
Lipoplexes have been externally conjugated to sonosensitive 
microbubbles, which are commonly used as contrast agents for 
diagnostic ultrasound. [ 12,13 ] Ultrasound is then used to generate 
acoustic cavitation, which localizes the release of the conjugated 
lipoplex and its uptake via a non-endocytotic pathway. However, 
the circulation lifespan of microbubbles is short (i.e., ≈minutes), 
which therefore can limit their utility in gene delivery. Addition-
ally, the externally conjugated lipoplexes are not protected from 
the previously described destabilization mechanisms. 
 Sonosensitive emulsions are an alternative to microbubbles 
for ultrasound-based gene delivery. Possessing greater in vivo 
stability and longer circulation lifespans (i.e., ≈hours), these 
sonosensitive emulsions possess a double emulsion structure 
of water-in-perfl uorocarbon-in-water (W 1 /PFC/W 2 ). [ 14–16 ] Water-
soluble payloads (e.g., non-viral DNA) can be encapsulated into 
the W 1 phase, rather than the conjugation of the payload to the 
exterior surface of the particle. The PFC phase inhibits payload 
diffusion and protects the payload from enzymatic degrada-
tion. Upon exposure to ultrasound above a threshold acoustic 
amplitude, the liquid PFC phase within the emulsion vapor-
izes into a gas, thus releasing the encapsulated payload. [ 17–19 ] 
This release process is termed acoustic droplet vaporization 
(ADV). [ 20 ] The use of focused, megahertz frequency range ultra-
sound to generate ADV could facilitate spatially and tempo-
rally controlled gene delivery at deep locations within the body. 
Similar to microbubbles, emulsions can be targeted to vascular 
or extravascular sites (depending on the droplet size) by conju-
gating targeting moieties to the droplet surface. [ 21,22 ] 
 The presented studies investigate the encapsulation of 
plasmid DNA (pDNA) with an enhanced green fl uorescent pro-
tein (eGFP) reporter, complexed in a lipoplex, in a sonosensitive 
double emulsion and its subsequent release using ADV. First, 
the encapsulation of the lipoplex was optically and electropho-
retically evaluated to determine the effect of the emulsifi cation 
process on the integrity of the pDNA. The acute cytotoxicity of 
the emulsion and one of its critical components, a fl uorophilic 
block copolymer, were evaluated. Next, we interrogated a range 
of acoustic amplitudes to determine the release effi ciency of a 
surrogate payload, fl uorescein, from the emulsion using ADV. 
Based on this initial release experiment, a subset of acoustic 
conditions was selected to investigate the in situ transfection 
of cells using ADV-triggered release of lipoplex. The impact 
of ADV on pDNA bioactivity as well as lipoplex uptake (i.e., 
sonoporation) was also studied. Finally, the co-delivery of lipo-
plex and Ficoll PM 400 using ADV was investigated as a means 
of increasing transfection effi ciency. 
 2.  Results and Discussion 
 2.1.  Characterization of Emulsions 
 Figure  1 A displays a schematic of the double emulsion structure 
used to encapsulate the various payloads. Figure  1 B contains 
an image of a lipoplex-loaded emulsion (LLE) containing Cy3-
labeled pDNA, which confi rms the localization of lipoplex within 
the W 1 droplets. Size distributions of the LLE and a representa-
tive image are shown in Figure  1 C. The mean droplet diameter 
is 2.9 µm with 3.1% (by number) of the droplets larger than 
10 µm in diameter. By comparison, Defi nity (Lantheus Medical 
Imaging)—a clinically approved, microbubble contrast agent 
has a mean particle diameter of 1.1–3.3 µm with 2% (by 
number) of the particles larger than 10 µm in diameter. Among 
the emulsions containing different payloads, there were no sta-
tistically signifi cant differences in mean droplet diameter or 
percent of payload encapsulated ( Table  1 ). 
 The stability of the emulsion in Dulbecco’s modifi ed Eagle 
media (DMEM) and plasma is shown in Figure S1 of the Sup-
porting Information. No statistically signifi cant differences 
between DMEM and plasma were observed at any of the time 
points. For DMEM, there was a 10.5% decrease in droplet con-
centration when comparing 6 h versus 0 h. Additionally in 
DMEM, there were small increases in the number percent of 
droplets greater than 10 µm in diameter when comparing 6 h 
versus 0 h (5.4%) and 6 h versus 1 h (6.6%). 
 The acoustic attenuation of the emulsion diluted at 2% (v/v) 
and 7% (v/v) was 0.42 ± 0.07 and 0.67 ± 0.11 dB cm −1 MHz −1 , 
respectively, in the range of 2.3–4.7 MHz (i.e., 69% bandwidth); 
these dilutions were used in the fl uorescein and lipoplex release 
studies, respectively. Thus, the diluted emulsion has a higher 
attenuation than water (i.e., 0.015 dB cm −1 MHz −1 ) and is similar 
in attenuation to soft tissue (i.e., ≈0.5–0.7 dB cm −1 MHz −1 ). [ 23,24 ] 
 2.2.  Cytotoxicity of Fluorosurfactants and Emulsion 
 Formulation of the primary emulsion (i.e., W 1 /PFC) requires a 
fl uorophilic surfactant to stabilize the resulting water droplets. 
The acute cytotoxicity of the perfl uoropolyether (PFPE)-poly-
ethylene glycol (PEG)-PFPE (i.e., PFPE-PEG-PFPE) copolymer, 
used to stabilize the primary emulsion in all formulations, was 
compared to that of the perfl uoropolyether with a terminal car-
boxylic acid group (PFPE-COOH) starting material. FC-770, a 
fl uorophilic solvent, was used to dissolve the PFPE-COOH or 
PFPE-PEG-PFPE for the in vitro studies.  Figure  2 A shows the 
viability of C3H/10T1/2 cells when incubated in FC-770 for 
6 h compared to 6 h incubations in common aqueous buffers 
used in cell culture. Cellular metabolic activity was lower in 
FC-770 compared to complete media or DMEM, though not 
statistically different from Opti-MEM. Fully fl uorinated liquids, 
such as Fluorinert or perfl uorocarbons, are immiscible with 
aqueous solvents including hydrophilic nutrients required for 
cell growth. However, these fl uorophilic liquids can dissolve 
extremely large amounts of oxygen. For example, the solubility 
of oxygen in FC-770 is ≈50% (v/v) at 25 °C, which is 10–20× 
higher than cell culture media. [ 25,26 ] 
 The concentration dependent toxicity of PFPE-COOH and 
PFPE-PEG-PFPE is shown in Figure  2 B. The experimental data 
were fi t to a 4 parameter sigmoidal (i.e., logistical) function that 
can be found in a previous publication. [ 27 ] Based on this regres-
sion, the half maximal inhibitory concentrations, in log(M), 
were −4.3 [−4.6, −4.0] and −3.6 [−3.9, −3.3] for PFPE-COOH and 
PFPE-PEG-PFPE, respectively. Thus, PFPE-PEG-PFPE is less 
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cytotoxic than PFPE-COOH. This fi nding is likely due to the 
ionizable carboxylic acid group in PFPE-COOH, which is not 
present in the PFPE-PEG-PFPE copolymer. Biomolecules such 
as proteins have been shown to interact with fl uorosurfactants 
containing charged, terminal groups while no interactions were 
observed with non-ionizable, terminal groups. [ 28 ] 
 For all emulsions, the concentration of PFPE-PEG-PFPE in 
PFP was 1.0% (w/w) or 1 × 10 −3  M . Based on Figure  2 B, this 
concentration of fl uorosurfactant in FC-770 was cytotoxic. How-
ever, as can be seen in Figure  2 C, when cells were incubated 
with blank emulsion diluted in DMEM, no cytotoxic effects 
were observed—even at 50% (v/v) which yielded a monolayer 
of droplets on top of the plated cells. The presence of overlying 
DMEM (Figure  2 C) likely mitigated the cytotoxicity of the 
PFPE-PEG-PFPE in the emulsion by decreasing the amount of 
fl uorosurfactant in direct contact with the cells. Higher meta-
bolic activity was observed in all test cases containing emulsion, 
relative to no emulsion. As mentioned previously, this could be 
due to oxygen loading within the perfl uoropentane (PFP) of the 
emulsion. Fluorophilic liquids, either non-emulsifi ed or emul-
sifi ed, have been shown to enhance cell viability and prolifera-
tion when added to culture media or hydrogel matrices. [ 29,30 ] 
 2.3.  Stability of pDNA during Emulsifi cation 
 The stability of the pDNA and lipoplex following sonication, 
which is the method used to form the primary emulsion, was 
assessed using electrophoresis. As seen in  Figure  3 , the parental 
pDNA band is present in all sonicated samples. Fragmenta-
tion, as indicated by the diffuse smear of faster-migrating 
species, was observed with both the pDNA (Lane 2) and lipo-
plex (Lane 4) following sonication, with greater fragmentation 
occurring with pDNA. Since the samples were in an ice bath 
during sonication, the sample temperature did not exceed 
10 °C during sonication. Thus, it is suspected that mechanical 
effects, such as hydrodynamic shear and cavitation impacted 
the integrity of the pDNA, rather than any thermal effects. Con-
densation of DNA using cationic agents can reduce fragmenta-
tion induced by sonication. [ 31 ] It is possible that not all pDNA 
Adv. Healthcare Mater. 2016, 5, 1764–1774
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 Figure 1.  A) Schematic illustration of the formation of the water-in-perfl uorocarbon-in-water (W 1 /PFC/W 2 ) double emulsion. In this example, the 
primary emulsion (i.e., W 1 /PFC) consists of a lipoplex payload contained within Opti-MEM (W 1 ). The W 1 droplets are stabilized by a fl uorosurfactant 
and dispersed within perfl uoropentane. The primary emulsion is emulsifi ed again in a solution of Polaxamer 188 (W 2 ), thereby allowing the primary 
emulsion to be dispersed in aqueous solutions. B) Schematic illustration of lipoplex release using acoustic droplet vaporization. Lipoplex-loaded double 
emulsion was added to cells plated on fi brin gels and subsequently exposed to focused ultrasound to release the lipoplex. The top left inset shows 
confocal fl uorescence images of double emulsion droplets containing lipoplexes (Cy3 labeled plasmid shown in green). The diameters of the droplets 
in images I–IV are 27,7.5, 5.1, and 2.5 µm, respectively. C) Number- and volume-weighted size distributions of a lipoplex-loaded double emulsion 
obtained using a Coulter Counter. The inset is an image of the double emulsion droplets (scale bar = 20 µm).
 Table 1.  Composition and characterization (n = 3) of double emulsions. 
All emulsions contained fl uorosurfactant and Polaxamer 188 that stabi-
lized the W 1 /PFC and PFC/W 2 interfaces, respectively. 
Payload(s) Aqueous component of 





None (i.e., blank) PBS 2.71 ± 0.10 –
Fluorescein sodium PBS 2.73 ± 0.30 93.3 ± 5.2
Lipoplex Opti-MEM 2.95 ± 0.21 93.7 ± 4.2
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was complexed into lipoplexes (Lane 4), and thus the non-com-
plexed pDNA was susceptible to fragmentation. No fragmen-
tation was observed when the lipoplex was incorporated into 
the LLE via sonication and then subsequently released by ADV 
(Lane 5). The presence of two liquid phases (i.e., W 1 and PFC) 
and fl uorosurfactant may have lessened the impact of sonica-
tion on the pDNA during the formation of the LLE. 
 2.4.  Fluorescein Release by Ultrasound 
 The relationship between the fraction of payload released 
from the emulsion and acoustic intensity was determined 
using an emulsion containing fl uorescein sodium in the W 1 
phase.  Figure  4 displays the sigmoidal release profi le, with 
a mechanical index (MI) ≥ 1.5 yielding signifi cant payload 
release relative to the no ultrasound condition (i.e., MI = 0). 
Spontaneous vaporization was not observed for any of the test 
conditions, thus indicating that the emulsion was thermally 
stable at 37 °C. Therefore, payload release at MI < 1.5 is likely 
due to outward diffusion of fl uorescein from the emulsion. 
Based on the regression, half maximal payload release occurred 
at MI = 1.46 [1.37, 1.55]. For diagnostic ultrasound, the cur-
rent limit set by the United States FDA for the MI, which is 
related to the acoustic intensity and a measure of the likeli-
hood for mechanical bioeffects, is 1.9. [ 32 ] Thus payload release 
from the emulsions can be triggered by acoustic intensities 
achievable by diagnostic ultrasound. Higher acoustic inten-
sities (i.e., MI > 1.9) can be achievable clinically using sys-
tems designed for therapeutic ultrasound (e.g., high intensity 
focused ultrasound). [ 33 ] 
 Since the population of droplets within the emulsion is poly-
disperse (Figure  1 C), the sigmoidal trend in payload release was 
expected. Previous studies have demonstrated an inverse trend 
between the acoustic intensity required for ADV (i.e., the ADV 
threshold) and droplet diameter. [ 34,35 ] As the acoustic intensity 
increases above the ADV threshold, a larger fraction of the total 
droplet population can undergo ADV. At the highest acoustic 
intensity tested (MI = 2.8), a fraction of unvaporized emulsion 
remained, as is evidenced by the incomplete release of fl uores-
cein in Figure  4 . Thus, the ADV threshold of these remaining, 
smaller sized droplets was above MI = 2.8. The generation of 
an emulsion with a monodisperse population of droplets would 
enable a steeper transition (i.e., a Heaviside step function) 
between the acoustic intensities that yield minimum versus 
maximum payload release. [ 36 ] 
 2.5.  In Situ Transfection 
 As an initial study, the transfectability of C3H/10T1/2 cells 
when incubated with varying concentrations of lipoplexes was 
determined ( Figure  5 A). A sigmoidal relationship was observed 
between the percent of cells transfected and the pDNA concen-
tration. Cell adherence, a measure of cell density normalized 
relative to the sham condition (i.e., 0 µg pDNA per well), as well 
as the percent of dead cells correlated inversely and directly, 
Adv. Healthcare Mater. 2016, 5, 1764–1774
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 Figure 2.  A) Metabolic activity (n = 5) of C3H/10T1/2 cells incubated in various solvents for 6 h. * p < 0.05. B) Metabolic activity (n = 5) of C3H/10T1/2 
cells incubated for 6 h in FC-770 containing varying concentrations of PFPE-COOH or a PFPE-polyethylene glycol (PEG)-PFPE copolymer. C) Metabolic 
activity (n = 5) of C3H/10T1/2 cells incubated for 6 h in blank double emulsion diluted in DMEM. * p < 0.05 versus 0% (v/v).
 Figure 3.  Gel electrophoresis confi rming stability of plasmid after ultra-
sound exposures. Lane 1) pDNA; lane 2) sonicated pDNA; lane 3) lipo-
plex; lane 4) sonicated lipoplex; lane 5) emulsifi ed lipoplex released by 
ultrasound (3.5 MHz, mechanical index (MI) = 2.5, 10 Hz pulse repetition 
frequency (PRF), 30 cycles); lane 6) 1 kb linear DNA ladder marker. The 
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respectively, with plasmid concentration. The cytotoxicity of 
lipoplexes at higher concentrations has been reported in the lit-
erature and is dependent on parameters such as the cell line as 
well as the lipid-pDNA molar charge ratio. [ 37–39 ] 
 Based on the release profi le obtained in Figure  4 , three 
acoustic amplitudes (i.e., MI = 1.5, 2.1, and 2.5) were selected to 
investigate the release of pDNA from the LLE using ADV. Addi-
tionally two ultrasound pulse lengths (3 or 30 cycles) were also 
examined. Figure  5 B shows the in situ transfection obtained 
using ADV. In the absence of ultrasound, 0.03 ± 0.01 µg of 
pDNA (or 4.7 ± 1.0% of the total pDNA encapsulated) was 
released from the LLE. This percent of non-selective release 
was not statistically different than that observed for fl uores-
cein. Exposure to ultrasound at MI = 1.5 and 3 cycles yielded 
0.18 ± 0.06 µg pDNA released (i.e., 32.6 ± 9.7%). The other 
acoustic conditions yielded similar pDNA release in the range 
of 0.27 ± 0.01 to 0.31 ± 0.03 µg (i.e., 47.1 – 54.3%). Therefore, 
ADV of the LLE signifi cantly increase payload (i.e., pDNA) 
release compared to the no ultrasound condition. Addition-
ally, as seen in Figure  4 , the same acoustic amplitudes released 
38.6–61.3% of fl uorescein encapsulated in the emulsion. Thus, 
ADV-induced payload release from the emulsion appears to be 
independent of encapsulated payload. This suggests that the 
acoustically driven formation of gas nuclei within the droplets 
was not impacted by payloads with different molecular weights 
or other physical properties. For MI = 1.5, pDNA release 
increased as the burst length increased from 3 to 30 cycles. 
Since all samples were exposed to ultrasound for the same total 
time, the effective “on-time” for pulsed ultrasound at 30 cycles 
is 10× greater than at 3 cycles. At a fi xed acoustic amplitude, the 
ADV threshold has been shown to correlate inversely with pulse 
duration, which would also support this trend at MI = 1.5. [ 40 ] 
 When exposed to LLE but not ultrasound, 7.4 ± 2.7% of the 
cells were transfected. Exposure to ultrasound at MI = 1.5 and 
3 cycles yielded 13.6 ± 3.3% transfection whereas the level of 
transfection ranged from 42.9 ± 8.0% to 54.0 ± 8.5% for the 
other acoustic conditions. Thus ADV of the LLE signifi cantly 
increases the level of transfection compared to the no ultrasound 
condition. Based on the sigmoidal regression in Figure  5 A, the 
following levels of transfection were expected based on the mass 
of pDNA released: 4.0% for 0.03 µg (i.e., LLE but no ultrasound), 
39.0% for 0.18 µg (i.e., LLE with MI = 1.5 and 3 cycles), and 45.1 
– 46.7% for 0.27–0.31 µg (i.e., LLE with all other acoustic condi-
tions). Thus, pDNA bioactivity does not appear to be affected by 
encapsulation and ADV-induced release. 
 Ultrasound alone at MI = 2.5 and 30 cycles—the highest 
acoustic amplitude and longest burst length tested—did not 
cause a statistically signifi cant decrease in cell adherence or 
Adv. Healthcare Mater. 2016, 5, 1764–1774
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 Figure 4.  Release profi le (n = 5) of fl uorescein sodium, a small molecular 
weight surrogate payload, at varying acoustic amplitudes (3.5 MHz, 
10 Hz PRF, 10 cycles). * p < 0.05 versus MI = 0.
 Figure 5.  A) Transfection effi ciency of C3H/10T1/2 cells, plated on fi brin gels, following a 6 h incubation with lipoplexes (1 µg pDNA/2 µL Lipofectamine 
2000). Percent cell adherence was normalized to the sham (i.e., 0 µg plasmid). * p < 0.05 versus 0 µg plasmid. B) Cell adherence, percent transfected, 
and percent dead are shown for in situ ADV of lipoplex-loaded emulsion (LLE) using various acoustic parameters. The amount of lipoplex released is 
expressed in terms of percent and total µg released. Statistically signifi cant differences ( p < 0.05) are denoted by letters with the following comparisons: 
a versus (-LLE,-US); b versus (-LLE,MI = 2.5, 30 cyc); c versus (+LLE,-US); d versus (+LLE,MI = 1.5, 3 cyc); e versus (+LLE,MI = 1.5, 30 cyc); f versus 
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cell death when compared to the sham condition. Compared 
to Figure  5 A, ADV of the LLE caused a greater decrease in 
cell adherence and increase in cell death for the same amount 
of pDNA released. As seen in the comparisons denoted in 
Figure  5 B, an increase in the MI (at a fi xed burst length) or an 
increase in the burst length (at a fi xed MI) caused a decrease in 
cell adherence and increase in cell death. Based on the results, 
ADV at MI = 1.5 and 30 cycles or MI = 2.1 and 3 cycles ena-
bles maximization of transfection and minimization of cell 
loss/death. Using ultra high-speed microscopy, velocities of 
5–25 m s −1 have been observed as a droplet phase transitions 
into a gas bubble during ADV. [ 41,42 ] Thus, the shear forces gen-
erated by ADV can cause deplating of adherent cells. [ 43 ] Gener-
ating ADV with a higher ultrasound frequency (i.e., >3.5 MHz) 
or a single burst of ultrasound could decrease cytotoxicity by 
reducing the likelihood for mechanical effects such as inertial 
cavitation. [ 44 ] Another potential strategy to minimize the bio-
effects of ADV is to formulate the LLE with a PFC that has a 
boiling point lower than PFP (i.e., 29 °C). It has been previously 
demonstrated that the acoustic intensity required for ADV is 
correlated with the boiling point of the PFC within the emul-
sion. [ 45 ] The impact of ADV on cellular viability can also be sig-
nifi cantly decreased by co-encapsulating the emulsion and cells 
within a hydrogel scaffold, thereby presumably dampening the 
forces generated during ADV. [ 19,46 ] 
 2.6.  Impact of ADV on pDNA Bioactivity 
and Cellular Transfectability 
 To further investigate the impact of ADV on the bioactivity of 
pDNA, a study was conducted where lipoplex was added to a 
sample of blank emulsion, either immediately before or after 
ADV (MI = 2.5 and 30 cycles) of the blank emulsion. As seen 
in  Figure  6 , there was no difference in the level of transfection 
obtained with this ex situ condition compared to the positive 
control (i.e., lipoplex without emulsion or ultrasound). Addition-
ally, there were no differences when adding the lipoplex before 
or after ADV. However, there was a decrease in cell adherence 
and increase in cell death that can be presumably attributed to 
the emulsion components, and not the acoustic exposure since 
ultrasound was applied in the absence of cells. This cellular 
bioeffect, observed when lipoplex was present, is in contrast 
to Figure  2 C where blank emulsion (alone) did not generate 
cytotoxic effects. Additionally, as can be seen when comparing 
the results for 0.5 µg pDNA per well for 1 h (Figure  6 ) or 6 h 
(Figure  5 A) incubations, an increase in incubation time lead to 
an increase in the level of transfection and death as well as a 
decrease in cell adherence. 
 Ultrasound can generate transient pores within the cell 
membrane, thus facilitating uptake of both naked DNA 
and lipoplexes. [ 47,48 ] This mechanism, termed sonoporation, 
enhances gene uptake via the interaction between ultrasound 
and microbubbles (i.e., acoustic cavitation). [ 49–51 ] To determine 
if ADV could generate sonoporative effects that could increase 
the uptake of lipoplex, lipoplex and blank emulsion were added 
to plated cells either immediately before or 1 h after ADV 
(MI = 2.5 and 30 cycles) of the emulsion. A 1 h wait time was 
chosen since cell membranes typically reseal within minutes 
following sonoporation. [ 52 ] As seen in Figure  6 , there was no 
difference in the level of transfection obtained with this in 
situ condition compared to the positive control (i.e., lipoplex 
without emulsion or ultrasound). Thus, based on these experi-
ments, ADV does not enhance lipoplex uptake. Sonoporation 
has been shown to increase the uptake of impermeable macro-
molecules as large as 2 MDa. [ 53 ] Comparatively, the lipoplexes 
generated using Lipofectamine 2000 (LF2000) range in diam-
eter from 0.76 to 1.0 µm, depending on the ratio of pDNA to 
LF2000. [ 54 ] Therefore, two scenarios could explain the observed 
results. First, the experimental conditions did not generate 
pores within the cell membrane that were large enough for the 
lipoplex to enter the cell. Second, the experimental conditions 
did generate pores that were large enough for the lipoplex to 
enter the cell, but cell viability and thus transgene expression 
was compromised as a result of the large pore(s). 
 2.7.  Co-Delivery of Lipoplex and Ficoll Using ADV 
 Ficoll PM 400—a high molecular weight copolymer of sucrose 
and epichlorohydrin—is extremely hydrophilic, thus yielding 
highly viscous solutions at elevated concentrations. It was ini-
tially hypothesized that incorporating signifi cant amounts of 
Ficoll into the W 1 phase of the LLE, the media overlying the 
cells during the ultrasound exposure, or both would reduce the 
diffusion of lipoplex following release by ADV. The reduced 
mobility of the lipoplex would have enabled spatial localization 
of transfection in the 2D cell culture. However, our attempts 
at demonstrating localization using this approach were unsuc-
cessful. It is likely that the ADV process enhanced the convec-
tion of the released lipoplex due to fl uid movement generated 
by the droplet phase transition. 
Adv. Healthcare Mater. 2016, 5, 1764–1774
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 Figure 6.  Cell adherence, percent transfected, and percent dead are 
shown for fi ve different conditions in which lipoplex (0.5 µg plasmid per 
well) was incubated with C3H/10T1/2 cells for 1 h. LP: positive control 
(i.e., lipoplex) without emulsion or ADV. LP with ex situ ADV:ADV of a 
blank emulsion occurred in a separate plate, with lipoplex added either 
before (i.e., exposed) or after ADV (i.e., non-exposed). The resulting lipo-
plex-containing solution was then added to plated cells. LP with in situ 
ADV:ADV occurred in wells containing plated cells, with lipoplex added 
either before or after ADV. * p < 0.05 versus LP. n = 4 wells with 3 fi elds 
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 In an initial study without any emulsion or ultrasound, 
 Figure  7 A–C displays the effect of varying Ficoll concentra-
tions on cell adherence, transfection, and death in the absence 
and presence of lipoplex. The inclusion of Ficoll did not affect 
cell adherence for either 0 or 1 µg pDNA per well. The inclu-
sion of Ficoll at 1% or 2% (w/v) in the overlying media caused 
an increase in the level of achievable transfection, yielding 
62.7 ± 8.8% transfection with 2% Ficoll versus 48.6 ± 4.6% 
transfection with 0% Ficoll. Therefore, Ficoll can enhance 
transfection even in the plateau region of the transfection dose 
response (Figure  5 A). This phenomenon could be potentially 
useful with cell lines that are diffi cult to transfect. The inclu-
sion of Ficoll alone did not affect cell death, though inclusion 
of lipoplex and 1% or 2% Ficoll caused an increase in cell death 
relative to the control (i.e., without lipoplex). 
 As seen in Table  1 , inclusion of Ficoll in the W 1 phase of 
the LLE did not affect the mean droplet diameter or percent 
payload encapsulated, relative to the LLE without Ficoll. Using 
an ex situ release setup (i.e., emulsion exposed to ultrasound 
in the absence of cells), ADV of LLEs with and without Ficoll 
yielded no difference in the amount of plasmid released 
(Figure  7 D). However, cells incubated with releasate from the 
LLE with Ficoll exhibited greater transfection compared to 
LLE without Ficoll (i.e., 40.1 ± 4.1% vs 35.9 ± 3.0%). A similar 
enhancement in transfection (i.e., 68.7 ± 7.1% vs 60.4 ± 7.4%) 
was observed with an in situ release setup ( Figure  8 ), where 
the LLEs with or without Ficoll were exposed to ultrasound 
in the presence of cells. Cell “islands” were generated by ras-
tering the focused ultrasound beam in a defi ned pattern, which 
yielded release of the lipoplex from the LLE and loss of cell 
adherence in the periphery of the islands. Tight localization of 
ADV and the resulting spatial control of cell adherence could 
have utility in in vitro applications of tissue regeneration, for 
example, in the patterning of cell co-cultures. [ 37,55 ] 
 To the best of our knowledge, this is the fi rst demonstration 
in the literature that Ficoll can be used to increase transfection. 
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 Figure 7.  Effect of Ficoll PM 400 on A) percent cell adherence , B) percent cells transfected, and C) percent dead cells. Plated C3H/10T1/2 cells were 
incubated with lipoplex (0 or 1 µg plasmid per well) for 6 h. D) The inclusion of 16.7% (w/w) Ficoll in the W 1 phase of the LLE increased the percent 
of cells transfected. LLE with or without Ficoll was exposed to ultrasound in a separate plate, with the releasate being added to plated cells. * p < 0.05 
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Since Ficoll is uncharged at biologically relevant pH, it is 
unlikely to facilitate electrostatic binding of the lipoplex to the 
cell membrane or endosomal uptake. We hypothesize that Ficoll 
increases the release of lipoplexes from the endosomes via one 
of two mechanisms. Ficoll could permeabilize the endosomal 
membrane, similar to results obtained with glycerol or ethylene 
glycol. [ 56,57 ] Alternatively, the hydrolysis of Ficoll could enhance 
osmotic swelling and eventual rupture of the endosome, sim-
ilar to the proton sponge hypothesis of polyethylenimine-based 
polyplexes. [ 10 ] 
 3.  Conclusions 
 This study demonstrates that pDNA, complexed in a lipoplex, 
can be stably encapsulated and released via ADV from a sono-
sensitive double emulsion. The pegylated fl uorosurfactant used 
in stabilizing the double emulsion and the overall emulsion 
displayed favorable biocompatibility with C3H/10T1/2 cells. 
Focused ultrasound at 3.5 MHz and an MI ≥ 1.5 yielded robust 
release of encapsulated payloads, irrespective of payload size, 
from the emulsion. The bioactivity of lipoplex was unaffected by 
ADV release while the ADV process did not yield any measure-
able sonoporative enhancement of transfection. Ficoll PM 400 
can be co-encapsulated with lipoplex in the double emulsion, 
yielding greater transfection than lipoplex alone. Additionally, 
cell adherence can be spatially patterned using ADV. The pre-
sented fi ndings have broad applicability in the control of tar-
geted gene delivery and future studies are aimed at the in vivo 
performance of these sonosensitive emulsions. 
 4.  Experimental Section 
 Formulation and Characterization of Emulsion : The double emulsion 
(W 1 /PFC/W 2 ) was prepared by modifying a previously published 
method. [ 16 ] The primary emulsion (W 1 /PFC) was formed by dissolving 
a nonionic fl uorosurfactant copolymer (PFPE-PEG-PFPE), synthesized 
from PFPE-COOH (Krytox 157 FSH, Dupont,Wilmington, DE, USA) and 
PEG (MW: 1000 g mol −1 , Alfa Aesar, Ward Hill, MA, USA), at 1.0% (w/w) 
in PFP (Strem Chemicals Inc., Newburyport, MA, USA). The PFP phase 
was combined with an aqueous W 1 phase, containing various payloads 
and solutes (described in later sections), at a volumetric ratio of 3.1:1. 
The phases were emulsifi ed, while on ice, using an immersion sonicator 
(20 kHz, model Q55, QSonica, Newton, CT, USA) for 30 s in continuous 
mode. The resulting primary emulsion was added dropwise at a 1:2 
volumetric ratio to a 1.0% (w/v) solution of Poloxamer 188 (Sigma-
Aldrich, St. Louis, MO, USA), dissolved in an aqueous buffer (W 2 phase, 
described in later sections), which was on ice and stirred at 700 rpm 
for 2 min. The resulting coarse double emulsion was blended using an 
immersion homogenizer (T10, IKA Works Inc., Wilmington, NC, USA) 
with 10 s on (speed 1), 30 s off, and 10 s on (speed 1). To minimize 
carryover of non-emulsifi ed payload, the emulsion was allowed to settle 
and the supernatant was replaced with fresh W 2 phase. All emulsion 
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 Figure 8.  In situ ADV was used to release lipoplex from LLEs, with and without Ficoll, and selectively deplate cells, thus forming “islands”. A) Sche-
matic showing the ultrasound raster pattern used to form islands, with the exposure points numbered sequentially from 1 to 41. LLE was added to 
the well before ultrasound exposure at points 1 and 9. A representative island was imaged for B) Hoescht, C) GFP, and D) propidium iodide. Scale 
bar: 1 mm. E) Transfection statistics are shown for islands formed with the LLEs, with or without Ficoll. * p < 0.05 versus Ficoll(-). n = 4 wells with 3 
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compositions are listed in Table  1 . For all experiments, the emulsions 
were used “as is” without any further processing or size separation. 
 Following formulation, each emulsion was sized using a Coulter 
Counter (Multisizer 4, Beckman Coulter Inc., Indianapolis, IN, USA) in 
the range of 1–30 µm. To assess stability, the emulsion was diluted at 
7% (v/v) in DMEM (Life Technologies, Grand Island, NY, USA) or ovine 
plasma and placed in a humidifi ed incubator at 37 °C with 5% carbon 
dioxide. The emulsion was periodically sampled and analyzed with a 
Coulter Counter. The acoustic attenuation of the emulsion, diluted at 2% 
(v/v) and 7% (v/v) in phosphate buffered saline (PBS), was measured 
with a single-element transducer (3.5 MHz, diameter: 19.1 mm, focal 
length: 50.8 mm, Olympus, Waltham, MA, USA) using a previously 
published method. [ 58 ] 
 Cell Culture : Cells of the mouse multipotent line C3H/10T1/2, clone 8 
(CCL-226, ATCC, Manassas, VA, USA) were cultured in complete media 
consisting of DMEM supplemented with 10% fetal bovine serum (Atlanta 
Biologicals Inc., Flowery Branch, GA, USA), 100 U mL −1 penicillin, and 
100 µg mL −1 streptomycin. The cells, grown in a humidifi ed incubator 
with 5% carbon dioxide, were continuously passaged to ensure 
confl uence never exceeded 80%. All experiments were performed with 
cells between passages 5–20. 
 Cytotoxicity of Fluorosurfactant and Emulsion : Cells were plated in 
complete media in a 96-well plate (Costar, Corning Inc., Corning, 
NY, USA) at 10 4 cells per well. This cell density was experimentally 
determined to yield the greatest assay sensitivity. The following day, the 
overlying media was removed and the cells were rinsed with DMEM. 
The cells were then incubated for 6 h with varying concentrations 
of fl uorosurfactant—either PFPE-COOH or the PFPE-PEG-PFPE 
copolymer—dissolved in Fluorinert FC-770 (3M, St. Paul, MN, USA). 
Fluorinert FC-770 was used as the solvent since both fl uorosurfactants 
are highly soluble in it. Additionally, the fl uorophilic solvent has a 
relatively high boiling point (95 °C) and low vapor pressure. As controls, 
cells were also incubated in either complete media, DMEM, Opti-MEM 
(Life Technologies), or FC-770 alone. After 6 h, the overlying media 
was removed, replaced with fresh complete media, and the cells were 
returned to the incubator. The following day, the viability of the cells was 
assessed using the alamarBlue assay (Invitrogen, Grand Island, NY, USA) 
according to the manufacturer’s instructions. The fl uorescence signal 
was analyzed with a plate reader (Ex: 560 nm, Em: 585 nm, SpectraMax 
M2e, Molecular Devices, Sunnyvale, CA, USA). An analogous cytotoxicity 
study was completed using varying concentrations of blank emulsion 
(i.e., without any payload) that contained Opti-MEM in the W 1 phase 
and was dispersed in DMEM. 
 Ultrasound Setup for ADV : A calibrated, single-element transducer—
utilized in the attenuation measurements—was used to generate 
ADV and thus trigger the release of payloads encapsulated within 
the emulsions. The transducer was driven by a signal generated by a 
function generator (33500B, Agilent Technologies, Santa Clara, CA, USA) 
and amplifi ed by a radiofrequency amplifi er (55 dB, A-300, Electronics & 
Innovation, Rochester, NY, USA). Samples exposed to ultrasound were 
presented in a 24-well plate (Fisher Scientifi c, Pittsburgh, PA, USA) 
that was fi xtured at the air–water interface of a temperature controlled 
(i.e., 37.0 ± 0.5 °C), degassed water tank. The transducer was positioned 
below the plate such that the axial focus of the transducer was 
perpendicular with respect to each well. Pulse-echo, implemented using 
a pulser/receiver (5073PR, Olympus) and oscilloscope (HDO4934, 
Teledyne LeCroy, Chestnut Ridge, NY, USA), was used to fi nely adjust the 
axial focus of the transducer within each well. The transducer, which was 
connected to a micropositioning system, was rastered across each well 
to expose the contents to ultrasound. 
 Stability of Plasmid during Emulsifi cation : Plasmid DNA (pDNA) 
with an enhanced green fl uorescent protein reporter (pEGFP-C1, 
4.7 kb, Clontech, Mountain View, CA, USA) was prepared and purifi ed 
by the University of Michigan Vector Core. Lipoplexes were generated 
by combining pDNA with LF2000 (Life Technologies), both diluted 
in Opti-MEM, at a ratio of 1 µg pDNA per 2 µL LF2000 according to 
the manufacturer’s instructions. This ratio of pDNA to LF2000 was 
experimentally determined to maximize transfection effi ciency while 
minimizing cytotoxicity. LLEs, containing lipoplexes as the payload and 
Opti-MEM as the solvent in the W 1 and W 2 phases, were formulated 
as described above. To visually confi rm the incorporation of pDNA in 
the LLE, pDNA was covalently labeled with the Cy3 Label IT Tracker 
reagent (Mirus Bio, Madison, WI, USA) according to the manufacturer’s 
instructions. LLE was formulated as previously described using the Cy3-
labeled pDNA. The resulting emulsion was imaged at the University of 
Michigan Microscopy & Imaging Laboratory using an inverted confocal, 
fl uorescence microscope (SP5X, Leica, Microsystems, Buffalo Grove, IL, 
USA) with a 100× objective. 
 Agarose gel electrophoresis was used to assess the stability of the 
pDNA during the emulsifi cation process and subsequent ultrasound-
triggered release. Solutions of either pDNA or lipoplex were exposed 
to low frequency ultrasound (i.e., 20 kHz) generated by the immersion 
sonicator as previously described. Additionally, LLE was exposed 
to high amplitude ultrasound from the single element transducer 
(MI = 2.5, 10 Hz PRF, 30 cycles—where 1 cycle is equivalent to 
1 acoustic wavelength) in order to release the encapsulated pDNA. The 
samples were analyzed using gel electrophoresis (60 V, 2 h), with a 1.0% 
(w/v) agarose gel prepared in Tris/Borate/EDTA (TBE) buffer. Prior to 
loading onto the gel, the lipoplex samples were dissociated with heparin 
(fi nal concentration: 7.5 U mL −1 ). The gel was subsequently stained 
with SYBR Gold Nucleic Acid Stain (Invitrogen) and imaged (Universal 
Hood II, Bio-Rad, Hercules, CA, USA). Control samples of non-sonicated 
plasmid and lipoplex as well as a 1 kb linear DNA ladder (N3232S, New 
England BioLabs, Ipswich, MA, USA) were also run on the gel. Equal 
masses of pDNA were loaded into each well of the gel. 
 Fluorescein Release Studies : To determine the acoustic amplitude 
required for payload release, emulsions were formulated as described 
above with fl uorescein sodium (1 mg mL −1 , Sigma-Aldrich) as a payload 
and PBS as the solvent in the W 1 and W 2 phases. The emulsion was 
diluted at 2% (v/v) in PBS and added to a 24-well plate. Each well 
was exposed to ultrasound at a constant acoustic amplitude for 
1 min. Following pulsed ultrasound exposure (10 Hz PRF, 10 cycles), 
the contents of each well were centrifuged to remove any remaining 
emulsion and the resulting supernatant was analyzed on a plate 
reader (Ex: 494 nm, Em: 521). The encapsulated mass of fl uorescein 
in the primary emulsion was determined by breaking the emulsion in a 
vacuum chamber at 5.8 kPa. The percent of fl uorescein released at each 
acoustic amplitude was determined by normalizing the mass released 
via ultrasound to the mass released under vacuum. The encapsulation 
effi ciency of the emulsion, defi ned as the fraction of payload in the 
primary emulsion (i.e., W 1 /PFC) compared to the fraction in the primary 
emulsion plus the W 2 phase, was also measured. 
 In Situ Transfection Using ADV : Fibrin gels were used as the substrate 
for cell culture since previous studies demonstrated that ADV could 
signifi cantly deplate cells cultured on tissue culture plastic. [ 43,59 ] Fibrin 
gels (5 mg mL −1 clottable protein, 0.36 mL total volume) were prepared in 
24-well plates by combining bovine fi brinogen (Sigma-Aldrich), dissolved 
in FluoroBrite DMEM (Life Technologies) containing 100 U mL −1 
penicillin and 100 µg mL −1 streptomycin, with bovine thrombin (2 U mL −1 , 
Thrombin-JMI, King Pharmaceuticals, Bristol, TN, USA). All solutions 
were degassed under vacuum prior to polymerization. Gels were allowed 
to polymerize for 30 min at room temperature prior to use. 
 Cells were subsequently plated on the gels at 1.2 × 10 4 cells 
per well in complete media (described previously) but containing 
FluoroBrite DMEM supplemented with 1 × 10 −3  M sodium pyruvate and 
4 × 10 −3  M L -glutamine (Figure  1 B). The cells were allowed to adhere to 
the gel overnight in an incubator. The following day, the overlying media 
was removed from the wells and replaced with FluoroBrite DMEM for 
30 min prior to the addition of either lipoplexes (0.1 – 1 µg pDNA per 
well) or LLE (7% v/v per well). The wells containing LLE were exposed 
to pulsed ultrasound (10 Hz PRF) of varying amplitudes (MI = 1.5, 
2.1, or 2.5) and burst lengths (3 or 30 cycles) for 30 s. The cells incubated 
for 6 hours with the lipoplex for all conditions before the overlying media 
was replaced with complete media. 
 The following day, the cells were stained with 16.2 × 10 −6  M Hoechst 
33342 (Invitrogen) and 15 × 10 −6  M propidium iodide (Invitrogen). 
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The cells were imaged with an inverted epifl uorescent microscope 
(DMIL, Leica Microsystems) using a 10× objective to determine the 
total number of cells (i.e., Hoescht+), total number of cells transfected 
(i.e., eGFP+), and total number of cells dead (i.e., propidium iodide+) 
per fi eld of view (FOV). The percent of cells that were transfected or 
dead was computed relative to the total number of cells in each FOV. 
Percent cell adherence was calculated as the average number of cells for 
an experimental condition divided by the average number of cells for the 
sham control (i.e., no lipoplex, LLE, or ultrasound). 
 The concentration of plasmid released from the LLE with various 
acoustic conditions was determined in an analogous experiment 
utilizing gels without plated cells. The released lipoplex was dissociated 
with heparin and then quantifi ed using Quant-iT PicoGreen reagent 
(Invitrogen). [ 54 ] To determine the loading of lipoplex within the LLE, the 
LLE was broken using an immersion sonicator (model 450, Branson, 
Danbury, CT, USA). 
 Effect of ADV on Plasmid Bioactivity and Transfection : Cells were 
plated on fi brin gels at 1.6 × 10 4 cells per well and allowed to adhere 
as previously described. The following day, the overlying media was 
replaced and the cells were incubated with lipoplex (0.5 µg pDNA per 
well, 1 h incubation) using the following ADV conditions. To determine 
the effect of ADV on the lipoplex, an ex situ setup was used where the 
lipoplex was added to a separate plate containing blank emulsion diluted 
in DMEM at 15% (v/v), either before (i.e., exposed) or after (i.e., non-
exposed) the emulsion was exposed to pulsed ultrasound (MI = 2.5, 
10 Hz PRF, 30 cycles). After ultrasound exposure, the contents of the 
wells were transferred to plated cells. To investigate the effect of ADV 
on cellular transfectability, an in situ setup was used where the blank 
emulsion was added to plated cells and ultrasound (MI = 2.1, 10 Hz 
PRF, 30 cycles) was applied in a spotwise manner (5 spots spaced 1 mm 
apart). Before each ultrasound exposure, 15 µL emulsion was added per 
spot to ensure suffi cient emulsion for ADV. Lipoplex was added either 
immediately before (i.e., exposed) or 1 h after (i.e., nonexposed) the set 
of 5 exposures. Following the 1 h incubation for all groups, the overlying 
media was replaced and the cells were incubated overnight. The 
following day, the cells were stained/imaged as previously described. 
 Co-delivery of Lipoplex and Ficoll Using ADV : Cells were plated on 
fi brin gels at 1.6 × 10 4 cells per well and allowed to adhere as previously 
described. The cells were incubated with lipoplex (1 µg pDNA per 
well) diluted in DMEM containing 0%–2% (w/v) Ficoll PM 400 
(GE Healthcare, Waukesha, WI, USA) for 6 h. The overlying media was 
removed and the cells were stained/imaged the following day as stated 
previously. 
 An emulsion containing lipoplex and 16.7% (w/w) Ficoll as payload 
in Opti-MEM as the solvent in the W 1 phase was formulated as 
described above. To demonstrate ultrasound-triggered release of both 
lipoplex and Ficoll, two separate experiments were conducted. First, 
LLE or LLE containing Ficoll were diluted at 7% (v/v) in DMEM in a 
24-well plate. The emulsions were exposed to ultrasound (MI = 2.1, 
10 Hz PRF, 3 cycles) and the contents of the wells were centrifuged 
to remove any remaining emulsion. The concentrations of released 
plasmid in the releasates were determined using the PicoGreen assay 
and the releasates were then added to plated cells for 6 h. The following 
day, the cells were stained/imaged as described previously. In a second 
experiment, LLE or LLE containing Ficoll were added to plated cells and 
ultrasound (MI = 2.5, 10 Hz PRF, 30 cycles) was applied in a grid-like 
manner to release the encapsulated lipoplex and selectively deplate cells, 
thus generating cell “islands”. The cells were incubated with the released 
lipoplex for 6 h and then stained/imaged the following day as stated. 
 Statistics : The data are expressed as the mean ± standard deviation 
of measured quantities. The number of independent, replicate 
measurements (n) is listed for each fi gure. The Tukey–Kramer method, 
evaluated in MATLAB, was used to determine statistically signifi cant 
differences between multiple groups for the in situ transfection data, 
with differences deemed signifi cant for  p < 0.05. Statistically signifi cant 
differences of all other data sets were determined with a Student’s  t -test 
with differences deemed signifi cant for  p < 0.05. The 95% confi dence 
interval of calculated values is listed in the following format: S [S L , S H ], 
where S is the average value, S L is the lower bound value, and S H is the 
upper bound value. 
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